From: RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
BRCA1 | Breast cancer susceptibility gene 1 |
BRCA2 | Breast cancer susceptibility gene 2 |
CRAd | Conditionally replicating adenovirus |
DMBA | 7,14-dimethylbenz[a]anthracene |
EGF | Epidermal growth factor |
EGFR | Epidermal growth factor receptor |
ELISA | Enzyme-linked immunosorbent assay |
EMT | Epithelial-mesenchymal transition |
ER | Estrogen receptor |
ErbB | Epidermal growth factor receptor |
ErbB2 | Epidermal growth factor receptor 2 |
HRT | Hormone replacement therapy |
Id2 | Inhibitor of DNA binding protein 2 |
IkB | Inhibitor of kappa B |
IkBα | Inhibitor of kappa Bα |
IKK-α | Inhibitor-kB kinase-α |
IgG | Immunoglobulin G |
IHC methods | Immunohistochemical methods |
IL-1 | Interleukin-1 |
IL-6 | Interleukin-6 |
IL-8 | Interleukin-8 |
Jak2 | Janus kinase 2 |
LECs | Luminal epithelial cells |
MaSCs | Mammary stem cells |
M-CSF | Macrophage colony-stimulating factor |
MECs | Myoepithelial cells |
MMTV | Mouse mammary tumor virus |
MPA | Medroxyprogesterone acetate |
NF-kB | Nuclear factor-kB |
OPG | Osteoprotegerin |
PCR | Polymerase chain reaction |
PR | Progesterone receptor |
PRLR | Prolactin receptor |
PTHrP | Parathyroid hormone-related protein |
RANK | Receptor activator of NF-kB |
RANKL | Receptor activator of NF-kB-ligand |
SREs | Skeletal-related events |
STAT5a | Signal transducer and activator of transcription 5a |
TGF-β | Transforming growth factor-β |
TNBC | Triple-negative breast cancer |
TNF | Tumor necrosis factor |
TNFR | Tumor necrosis factor receptor |
TNFRSF11A | TNF Receptor Superfamily Member 11a |
TNF-α | Tumor necrosis factor-α |
TRAF | TNF receptor-associated factor |
TRAF2 | TNF receptor-associated factor-2 |
TRAIL | TNF related apoptosis-inducing ligand |
TRANCE | TNF-related activation-induced cytokine |